Please login to the form below

Not currently logged in
Email:
Password:

NSCLC

This page shows the latest NSCLC news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

A year ago Opdivo gained NICE approval for second line use in the biggest single cancer patient group, non-small cell lung cancer (NSCLC), but its main immunotherapy rival, MSD’s

Latest news

More from news
Approximately 111 fully matching, plus 328 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • The good, the bad and the ugly The good, the bad and the ugly

    Though its main competitor, BMS’Opdivo, was first to the NSCLC market, Merck’s frontline trial for Keytruda succeeded whereas Opdivo’s failed.

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.

  • Pharma deals during October 2014 Pharma deals during October 2014

    This month's big pharma collaborations are in oncology, firstly where Novartis and BMS have entered a clinical collaboration for a combination of drugs in non-small cell lung cancer (NSCLC). ... Zykadia is approved in the US for patients with anaplastic

  • Oncology drugs under AMNOG: part two Oncology drugs under AMNOG: part two

    Xalkori: Symptom improvement and quality of life gains add benefit. In the case of Xalkori (crizotinib), Pfizer's product targeting a subsegment of non-small cell lung cancer (NSCLC) in which ... Outcome. Xalkori(crizotinib) in NSCLC. No OS benefit shown

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Virgo Health

Virgo Health is an award-winning global healthcare communications and medical education agency comprising specialists with some of the best skills,...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics